Denosumab: Current Use in the Treatment of Primary Bone Tumors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28732103.
- Also identified by DOI 10.3928/01477447-20170627-04.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Denosumab, a human monoclonal antibody that inhibits bone resorption by binding on the receptor activator of the nuclear factor kappa-β ligand, has recently emerged as an additional option in the treatment of musculoskeletal osteolytic tumors. This article focuses on the recent literature regarding the effectiveness of denosumab in the management of giant cell tumor, multiple myeloma, aneurysmal bone cyst, and osteosarcoma. The mechanism of action of denosumab in the management of these tumors and the associated side effects are discussed in detail. [ Orthopedics. 2017; 40(4):204-210.].
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Bone Neoplasms
- Denosumab